SCHEMBL5392452

SCHEMBL5392452

Cc1ccccc1CNC(=O)c1ccccc1-c1ccccc1C(=O)N(CCC(=O)O)CCc1cccnc1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.50
KMT2A Q03164 2/20 0.50
ALDH1A1 P00352 5/20 0.49
KCNK3 O14649 1/20 0.48
KCNH2 Q12809 1/20 0.48
USP2 O75604 1/20 0.45
HPGD P15428 3/20 0.45
MAPK1 P28482 1/20 0.43
LMNA P02545 1/20 0.42
TSHR P16473 1/20 0.42
KDM4E B2RXH2 1/20 0.42
TBXAS1 P24557 4/20 0.42
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5402306 0.93 KMT2A (0.55) HTTKMT2AALDH1A1KCNK3KCNH2
SCHEMBL5409483 0.92 HTT (0.51) HTTKMT2AALDH1A1KCNK3KCNH2
SCHEMBL5401671 0.91 HPGD (0.52) HTTALDH1A1HPGDLMNAKDM4E
SCHEMBL5398795 0.90 MAPK1 (0.49) HTTKMT2AALDH1A1HPGDMAPK1
SCHEMBL5408552 0.90 HTT (0.59) HTTKMT2AALDH1A1USP2HPGD
SCHEMBL5412154 0.90 HTT (0.62) HTTKMT2AALDH1A1USP2HPGD
SCHEMBL5402212 0.89 KMT2A (0.50) HTTKMT2AALDH1A1KCNK3KCNH2
SCHEMBL5392440 0.89 KCNK3 (0.52) HTTKMT2AALDH1A1KCNK3KCNH2
SCHEMBL5414282 0.88 KMT2A (0.53) HTTKMT2AALDH1A1KCNK3KCNH2
SCHEMBL5409151 0.88 HTT (0.62) HTTKMT2AALDH1A1USP2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285680-B2 β-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-10-23 US disclosed
US-20050256160-A1 Beta-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2005-11-17 US disclosed
EP-1533294-A1 BETA-ALANINE DERIVATIVE AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256160-A1 Beta-alanine derivatives and the use thereof TGFB1, PML, APOB HTT 3791/4885KMT2A 2451/4885ALDH1A1 1256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.